Arcutis Biotherapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands, except share data)(unaudited)
Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity
Shares · Amount
Balance—December 31, 2023	96,787,349	$9	$1,070,558	$4	$(981,904)	$88,667
Issuance of shares of common stock net of discount and issuance costs of $10,820	18,157,895	3	161,679	—	—	161,682
Issuance of common stock upon the exercise of stock options	21,863	—	82	—	—	82
Issuance of common stock upon the vesting of restricted stock units	538,330	—	—	—	—	—
Stock-based compensation expense	—	—	10,030	—	—	10,030
Unrealized loss on marketable securities	—	—	—	(116)	—	(116)
Foreign currency translation adjustment	—	—	—	(21)	—	(21)
Net loss	—	—	—	—	(35,382)	(35,382)
Balance—March 31, 2024	115,505,437	12	1,242,349	(133)	(1,017,286)	224,942
Issuance of common stock upon the exercise of stock options	147,490	—	806	—	—	806
Issuance of common stock upon the vesting of restricted stock units	443,365	—	—	—	—	—
Shares issued pursuant to the employee stock purchase plan	383,975	—	649	—	—	649
Stock-based compensation expense	—	—	12,523	—	—	12,523
Unrealized loss on marketable securities	—	—	—	(127)	—	(127)
Foreign currency translation adjustment	—	—	—	(34)	—	(34)
Net loss	—	—	—	—	(52,332)	(52,332)
Balance—June 30, 2024	116,480,267	$12	$1,256,327	$(294)	$(1,069,618)	$186,427

ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands, except share data)(unaudited)
Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity
Shares · Amount
Balance—December 31, 2022	61,037,403	$6	$930,425	$(1,086)		$(719,764)	$209,581
Issuance of common stock upon the exercise of stock options	31,497	—	100	—		—	100
Issuance of common stock upon the vesting of restricted stock units	285,314	—	—	—		—	—
Lapse of repurchase rights related to common stock issued pursuant to early exercises	3,718	—	—	—		—
Stock-based compensation expense	—	—	9,479	—		—	9,479
Unrealized loss on marketable securities	—	—	—	724		—	724
Foreign currency translation adjustment			(52)		(52)
Net loss	—	—	—	—		(80,100)	(80,100)
Balance—March 31, 2023	61,357,932	6	940,004	(414)		(799,864)	139,732
Issuance of common stock upon the exercise of stock options	35,700	—	74	—		—	74
Issuance of common stock upon the vesting of restricted stock units	77,221	—	—	—		—	—
Lapse of repurchase rights related to common stock issued pursuant to early exercises	3,719	—	—	—		—	—
Shares issued pursuant to the employee stock purchase plan	155,446	—	993	—		—	993
Stock-based compensation expense	—	—	10,578	—		—	10,578
Unrealized gain on marketable securities	—	—	—	128		—	128
Foreign currency translation adjustment	—	—	—	(6)		—	(6)
Net loss	—	—	—	—		(70,991)	(70,991)
Balance—June 30, 2023	61,630,018	$6	$951,649	$(292)		$(870,855)	$80,508

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.